Bookmark

Add to MyYahoo RSS

Copd News

News on Copd continually updated from thousands of sources around the net.

37 min ago | EurekAlert!

New research to tackle treatment for lung disease

Research into improving treatment for patients with one of the UK's most common respiratory diseases has received a 810,000 funding boost.

Comment?

Related Topix: Medicine, Health, Chronic Obstructive Pulmonary Disease

Thu Jul 24, 2014

In-PharmaTechnologist.com

GSK's declining Advair sales to be propped by respiratory portfolio

GlaxoSmithKline has issued upbeat guidance despite a 12% fall in sales of its blockbuster asthma and COPD drug Advair, as new products enter the respiratory drug market.

Comment?

Related Topix: Biotech, Medicine, GlaxoSmithKline, Asthma, Health, Fluticasone (generic), Flovent, Food and Drug Administration

Sat Jul 19, 2014

Thomasville Times Enterprise

Asthma, COPD talk planned at Archbold

Tens of millions of people in the U.S. suffer from some form of lung disease. Two of the most common types of lung disease are asthma and chronic obstructive pulmonary disease , both of which are prevalent in Georgia.

Comment?

Related Topix: Medicine, Pulmonary Medicine, Georgia, Common Cold

Thu Jul 17, 2014

US Pharmacist

Catching Your Breath: Managing COPD Exacerbations

ABSTRACT: Chronic obstructive pulmonary disease remains the third leading cause of death in the United States, and the number of COPD deaths is projected to increase by 30% within the next 10 years.

Comment?

Related Topix: Medicine, Health, Chronic Obstructive Pulmonary Disease, Chronic Bronchitis, Genetics

Wed Jul 16, 2014

Sys-Con Media

GSK and Theravance Announce Initiation of Phase III Programme With...

IMPACT is the first pivotal phase III study in a programme to evaluate a once-daily closed triple combination treatment of an inhaled corticosteroid ; a long-acting muscarinic antagonist ; and a long-acting beta2-adrenergic agonist in patients with COPD.

Comment?

Related Topix: Biotech, GlaxoSmithKline, Startups, Theravance, Medicine, Healthcare Industry, Chronic Obstructive Pulmonary Disease

Sat Jul 12, 2014

Medical News Today

COPD and the effect of depressed mood on pulmonary rehab completion

Researchers from The Miriam Hospital have found that people with Chronic obstructive pulmonary disease who are also depressed have difficulty sticking to a pulmonary rehabilitation program.

Comment?

Related Topix: Health, Chronic Obstructive Pulmonary Disease, Depression, Providence, RI

Wed Jul 09, 2014

EurekAlert!

Miriam Hospital study examines effect of depressed mood on pulmonary rehab completion

Researchers from The Miriam Hospital have found that people with Chronic obstructive pulmonary disease who are also depressed have difficulty sticking to a pulmonary rehabilitation program.

Comment?

Related Topix: Medicine, Health, Chronic Obstructive Pulmonary Disease, Depression, Preventive Medicine, Providence, RI

Recordpub.com

Coming up At Robinson Memorial

Family members, friends and caregivers are also welcome. July topic: "COPD and Irritants."

Comment?

Related Topix: Medicine, Health, Chronic Obstructive Pulmonary Disease

B3C

Domainex Reports Success of its Lead Compound in Pre-clinical Model of COPD and Secures A 1. ...

Domainex Ltd , a UK-based drug discovery company developing first-in-class small-molecule inhibitors of two closely-related pro-inflammatory kinases - TBK1 and IKK-epsilon , today announced that its lead compound has demonstrated a more potent effect in a key model of chronic obstructive pulmonary disease than either roflumulast or a p38 inhibitor.

Comment?

Related Topix: Medicine, Health, Chronic Obstructive Pulmonary Disease

Recordpub.com

Treat COPD with education, communication

This is a frightening A potential reality for an estimated 24 A million Americans with A chronic obstructive pulmonary disease , a progressive and debilitating lung disease that makes it difficult to breathe.

Comment?

Related Topix: Medicine, Health, Chronic Obstructive Pulmonary Disease

Mon Jul 07, 2014

Sys-Con Media

Anoro(R) Ellipta(R) (Umeclidinium/Vilanterol) Gains Approval in Japan for the Treatment of COPD

Anoro is a once-daily combination treatment comprised of two bronchodilators, umeclidinium , a long-acting muscarinic antagonist , and vilanterol , a long-acting beta2 agonist , in a single inhaler, the Ellipta.

Comment?

Related Topix: Medicine, Health, Startups, Theravance, Biotech, GlaxoSmithKline, Healthcare Industry, Chronic Obstructive Pulmonary Disease, Chronic Bronchitis

•••
•••
•••
•••
•••
•••
•••
•••